EcoDrugPlus

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSSAUG00010027334
Gene Symbol: NAMPT
3 Cross references
225 Possible Orthologues:

Nischarin

Ensembl ID : ENSSAUG00010022846
Gene Symbol: NISCH
3 Cross references
208 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSSAUG00010022845
Gene Symbol: NOTCH1
3 Cross references
201 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSSAUG00010005489
Gene Symbol: NFKB1
1 Cross references
200 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSSAUG00010024752
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSSAUG00010009187
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSSAUG00010020924
Gene Symbol: NR1H4
3 Cross references
386 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSSAUG00010005098
Gene Symbol: NR3C1
3 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSSAUG00010018162
Gene Symbol: NR3C1
1 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSSAUG00010007622
Gene Symbol: NR3C2
1 Cross references
209 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSSAUG00010016509
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSSAUG00010002649
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).